You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 48 No. 4, April 1991 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (141)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Intermittent vs Maintenance Medication in Schizophrenia

Two-Year Results

Marvin I. Herz, MD; William M. Glazer, MD; Marcelle A. Mostert, MD; Michael A. Sheard, MD; Herman V. Szymanski, MD; Hisham Hafez, MD; Mahmud Mirza, MD; Josef Vana, MD

Arch Gen Psychiatry. 1991;48(4):333-339.


Abstract



• This is a 2-year, double-blind, placebo-controlled study of 101 patients, evaluating the relative efficacy of intermittent medication (given only when the patient shows early signs of relapse) compared with moderate doses of maintenance medication for stable schizophrenic outpatients. Patients were dropped from the study if they had three prodromal episodes in 1 year or if an episode lasted more than 9 weeks. Fourteen percent of patients given maintenance treatment were dropped from the study compared with 46% of intermittently treated patients. Relapse rates were 16% for patients given maintenance treatment and 30% for intermittently treated patients, a nonsignificant difference. Intermittently treated patients were receiving significantly less medication, but there were no differences found in drug side effects. There appears to be no advantage in using the intermittent approach, but we found that the use of an early intervention strategy reduced the relapse and rehospitalization rates for these patients.



Author Affiliations



From the Department of Psychiatry, State University of New York, Buffalo, (Drs Herz, Mostert, Szymanski, Mirza, and Vana); the Department of Psychiatry, Yale University, New Haven, Conn (Drs Glazer and Sheard); and Nashua (NH) Brookside Hospital (Dr Hafez).


Footnotes



Accepted for publication May 31, 1990.

Dr Herz is now with the University of Rochester (NY) Medical Center.

Reprint requests to Department of Psychiatry, University of Rochester Medical Center, 300 Crittenden Blvd, Rochester, NY 14642 (Dr Herz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes and the Schizophrenia Consensus Group of the British A
J Psychopharmacol 2011;25:567-620.
ABSTRACT | FULL TEXT  

Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia
Rosenheck et al.
Clin Trials 2011;8:196-204.
ABSTRACT | FULL TEXT  

Comparison of the effectiveness of depot antipsychotics in routine clinical practice
Shajahan et al.
The Psychiatrist 2010;34:273-279.
ABSTRACT | FULL TEXT  

First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies
Haddad et al.
Br. J. Psychiatry 2009;195:S20-S28.
ABSTRACT | FULL TEXT  

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses
Turner and Stewart
J Psychopharmacol 2006;20:20-37.
ABSTRACT  

The Role of Early Warning Symptoms in the Detection and Prevention of Relapse in Schizophrenia
Fitzgerald
Aust N Z J Psychiatry 2001;35:758-764.
ABSTRACT | FULL TEXT  

A Program for Relapse Prevention in Schizophrenia: A Controlled Study
Herz et al.
Arch Gen Psychiatry 2000;57:277-283.
ABSTRACT | FULL TEXT  

The Rationale and Ethics of Medication-Free Research in Schizophrenia
Carpenter et al.
Arch Gen Psychiatry 1997;54:401-407.
ABSTRACT  

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia: The Effects of Dose Reduction and Family Treatment
Schooler et al.
Arch Gen Psychiatry 1997;54:453-463.
ABSTRACT  

Clinical Risk Following Abrupt and Gradual Withdrawal of Maintenance Neuroleptic Treatment
Viguera et al.
Arch Gen Psychiatry 1997;54:49-55.
ABSTRACT  

Behavioral vs Biochemical Prediction of Clinical Stability Following Haloperidol Withdrawal in Schizophrenia
van Kammen et al.
Arch Gen Psychiatry 1995;52:673-678.
ABSTRACT  

Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT  

Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia
Marder et al.
Arch Gen Psychiatry 1994;51:280-287.
ABSTRACT  

Sleep in Schizophrenic Patients On and Off Haloperidol Therapy: Clinically Stable vs Relapsed Patients
Neylan et al.
Arch Gen Psychiatry 1992;49:643-649.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.